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Risk of radiocontrast nephropathy in patients with and without diabe-
tes mellitus. The present study was designed to test whether altered
renovascular reactivity is associated with the increased risk of radio-
contrast nephropathy (RCN) in diabetics. We studied 50 patients (24
diabetics, 26 nondiabetics) with chronic renal insufficiency undergoing
cardiac catheterization. Patients were randomized to receive either
saline, or one of three renal vasodilator/diuretic drugs—dopamine,
atrial natriuretic peptide (ANP), or mannitol—by intravenous infusion
during cardiac catheterization. Renal blood flow (RBF) was measured
by thermodilution at various time points during cardiac catheterization.
RCN was defined as an increase in Crof at least 25% over baseline
within 48 hours of cardiac catheterization. Baseline Cr and creatinine
clearance were similar in diabetics and nondiabetics (2.6 0.2mg/dl vs.
2.4 0.1 mg/dl, and 32 3 mllmin vs. 34 3 mI/mm, respectively), but
baseline RBF was significantly lower in diabetics (154 21 mI/mini
kidney vs. 277 36 mI/mm/kidney, P < 0.05). Diabetic patients
exposed to the three vasodilator/diuretic drugs had the greatest increase
in RBF throughout cardiac catheterization. The incidence of RCN
among the diabetics receiving those drugs was 83%, 83% and 75%, in
the dopamine, ANP and mannitol groups, respectively. In contrast,
among the nondiabetics in each of those groups the incidence of RCN
was zero (all P < 0.05, diabetics vs. nondiabetics). In the saline control
group the rates of RCN in the diabetics and nondiabetics were 43% and
38%, respectively (NS). In conclusion, the increased risk of RCN
among diabetics was associated with exaggerated renovascular reactiv-
ity: baseline vasoconstriction and enhanced vasodilation with vasodi-
lator/diuretic drugs. These same drugs, however, reduced the risk of
RCN in nondiabetic patients.
The incidence of radiocontrast nephropathy (RCN) depends
on a number of risk factors, the best established of which are
chronic renal insufficiency and diabetes mellitus [1—4]. The
incidence of RCN in azotemic diabetic patients undergoing
cardiac catheterization has been reported to be at least 50% in
some studies [5—7].
The proposed pathogenesis of RCN includes roles for renal
ischemia and intratubular obstruction [8, 9]. Thus, efforts to
prevent RCN have focused on agents which increase renal
blood flow (RBF), cause a diuresis, or do both. Among agents
in the last category are mannitol [10], atrial natriuretic peptide
(ANP) [7, 11], and dopamine [121. Thus far, investigations of
the preventive efficacy of these agents have been inconclusive.
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Although several studies have examined the prophylactic po-
tential of mannitol in RCN, it remains unproven [13—15]. We
previously compared the incidence of RCN in a group of
high-risk patients who received mannitol with that of a similar
group receiving ANP, and found no difference between them
[7]. We have also reported that dopamine, compared with
saline, conferred no protection against RCN in a high-risk
patient population [12]. In both those studies, patients with
diabetes mellitus had a higher incidence of RCN than nondia-
betic patients.
The mechanism by which diabetes mellitus predisposes pa-
tients to RCN is unclear. Diabetes mellitus appears to be
associated with abnormal resting renal hemodynamics [16], and
exaggerated renal vasodilation with stimulation [17, 18]. One
study in diabetic rats implicated altered renovascular reactivity
in the pathogenesis of RCN [19]. This relationship has not yet
been investigated systematically in human subjects.
We designed the present study to answer two questions: (1)
Do patients with chronic renal failure with and without diabetes
mellitus differ in their renal hemodynamic response to contrast
medium infusion alone or in the presence of experimental renal
vasodilator/diuretic drugs? and, if so, (2) Is there a relationship
between those immediate renal hemodynamic alterations and
the subsequent development of RCN? We found that the
experimental drugs were associated with abnormal renovascu-
lar reactivity in patients with diabetes mellitus which, in turn,
was associated with an increased risk of RCN. These same
drugs significantly reduced the risk of RCN among the nondia-
betic patients.
Methods
Patient selection
The patient group in the present study has been described in
part in previous reports [7, 12, 20]. All patients with chronic
renal failure, defined as a stable plasma creatinine concentra-
tion (ncr) greater than or equal to 1.8 mg/dl, undergoing elective
cardiac catheterization, were considered eligible for inclusion in
the study. Patients were excluded if they had New York Heart
Association Class IV congestive heart failure, evidence of liver
dysfunction, hemodynamic instability, allergy to contrast me-
dium, prior exposure to contrast medium within seven days of
the experimental protocol, or were pregnant. Before enrollment
in the study, all patients gave written informed consent to
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participate in the research protocol approved by the Institu-
tional Review Committee at Cooper Hospital/University Med-
ical Center. A medical history was taken and a physical
examination performed with attention to the exclusion criteria,
current medications, the cause of the chronic renal failure, and
underlying illnesses.
Experimental protocol
All patients received an intravenous infusion of 0.45% so-
dium chloride at 100 mllhr beginning 12 hours before, and
continuing throughout the cardiac catheterization. Patients
were randomly assigned in a double-blind fashion to receive
either saline or one of three experimental drugs by intravenous
infusion. The infusions began immediately after full instrumen-
tation for the cardiac catheterization procedure and continued
for a total of two hours (about twice the duration of the
catheterization procedure itself). We randomized the patients in
two separate sets: saline (Group 1) versus dopamine (Group 2),
and ANP (Group 3) versus mannitol (Group 4). Specifically,
Group 1 received 0.45% sodium chloride at 100 milhr, Group 2,
dopamine at 2 j.tg/kg/min in 0.45% sodium chloride at 100 ml/hr,
Group 3, ANP (Merck, Sharp and Dohme, Rahway, New
Jersey, USA), 50 g bolus, followed by an infusion of 1 pg/min
in 0,45% sodium chloride at 100 ml/hr, and Group 4, mannitol,
15 g/dl in 0.45% sodium chloride at 100 ml/hr.
Cardiac catheterization was performed by the percutaneous
femoral approach. One arterial and two venous sheaths were
placed (time 0, t = 0). A Swan-Ganz catheter was placed with
its tip in the pulmonary artery for measurement of right heart
pressures. A catheter was advanced into the left renal vein for
serial measurements of RBF (see below). A pigtail catheter was
advanced into the left ventricle for ventriculography. All pa-
tients underwent a single ventriculogram, completed by 15
minutes into the catheterization (t = 15), followed by coronary
angiography, completed by 65 minutes (t = 65). The contrast
medium used in all cases was MD76 (66% diatrizoate meglu-
mine, 10% diatrizoate sodium), an ionic high-osmolality me-
dium. A record was made of total fluid intake and output during
the 24 hour period after cardiac catheterization.
Measurement of renal hemodynamics
RBF was measured using a 7-French dual-thermistor ther-
modilution catheter (Webster Labs, Baldwin Park, California,
USA), as described in detail previously [7, 12, 20, 21]. In brief,
the catheter was passed through the femoral vein sheath and
fluoroscopically guided into the left renal vein without the use
of contrast medium. To determine RBF, we used a continuous
thermodilution technique, injecting room-temperature 5% dex-
trose through the catheter with a Harvard pump (Harvard
Apparatus Co, Millis, Massachusetts, USA) at 50 mI/mm until
the temperature deflections recorded from the internal and
external thermistors were stable. Three or four replicate RBF
measurements were made at approximately one-minute inter-
vals at each time point. RBF was measured at t = 0 (baseline),
t = 5 (after the drug infusion was begun but before the
ventriculogram), t 15 (immediately after the ventriculogram),
and t = 65 (after the coronary angiogram). Renovascular
resistance (dynes • sec/cm5) was calculated as [(MAP — RAP)
80,000] ÷ RBF, where MAP is mean arterial pressure and RAP
is right atrial pressure.
Drug group N Cr mg/di
Cra
mi/mm
RBF mit
mm/kid,
1. SAL 15 2.7 0.2 29 3 247 55
(+)DM 7 3.1 0.2" 23 3 175 34
(—)DM 8 2.3 0.1 34 5 308 96
2. DOP 15 2.4 0.2 32 4 171 24
(+)DM 7 2.6 0.3 33 9 100 31b
(—)DM 8 2.2 0.1 31 2 223 22
3. ANP 10 2.4 0.2 35 5 177 37
(+)DM 6 2.5 0.3 34 5 139 30
(—)DM 4 2.3 0,3 37 10 242 80
4. MAN 10 2.5 0.3 38 5 278 47
(+)DM 4 2.2 0.1 41 9 214 72
(—)DM 6 2.7 t 0.4 36 7 331 58
Groups 2 to 4 35 2.4 0.1 35 3 204 21
(+)DM 17 2.4 0.2 36 4 144 26"
(—)DM 18 2.4 0.2 34 3 261 27
Groups I to 4 50 2.5 0.1 33 2 218 23
(+)DM 24 2.6 0.2 32 3 154 21"
(—)DM 26 2.4 0.1 34 3 277 36
Laboratory measurements
A blood specimen for P was obtained upon entry into the
study. 1Cr measurement was repeated at t = 0 (baseline), 24 and
48 hours after the catheterization, and daily thereafter until it
returned to the baseline level or stabilized. PCr was determined
by a modified Jaffe end-point assay in a Hitachi 737 autoana-
lyzer (Boehringer-Manheim, Indianapolis, Indiana, USA). We
defined RCN as a rise in PCr of at least 25% over baseline by 48
hours after the catheterization. Creatinine clearance (Car) was
estimated by the formula of Cockcroft and Gault [221 for all
patients, and measured using a 12-hour urine collection for the
first 18 patients enrolled in the study.
Statistical analysis
All continuous data were tabulated and analyzed as mean
SEM. Paired t-tests or independent t-tests were used to deter-
mine differences within or between groups and subgroups,
respectively. Differences between proportions were assessed
using Chi-squared analysis or Fisher exact test, as appropriate.
Linear regression analysis and one-way analysis of variance for
repeated measures were performed according to standard pro-
cedures. Differences were considered significant at P < 0.05.
Results
Patient characteristics
Fifty patients met the criteria for enrollment in the study and
completed the described protocol. Table 1 summarizes their
baseline characteristics, according to experimental group and
the presence or absence of diabetes mellitus. The mean baseline
'Cr of the population as a whole was 2.5 0.1 mg/dl and was
similar in all groups. Within each group, PCr was similar in
patients with diabetes mellitus and those without, with the
exception of Group 1, in which the mean P,,, was significantly
higher in patients with diabetes mellitus. The mean estimated
Table 1. Baseline patient characteristics
Abbreviations are: (+)DM, patients with diabetes mellitus; (—)DM,
patients without diabetes mellitus.
a Car, creatinine clearance, according to the formula of Cockcroft
and Gault [22]b p < 0.05 vs. (—)DM
Time, minutes
Fig. 1. Mean percent change in RBF during cardiac catheterization for
patients in Groups I to 4 combined. Symbols are: (0) patients with
diabetes mellitus; (0) patients without diabetes mellitus. Ventriculo-
gram performed immediately before t = 15; coronary angiogram per-
formed between t = 15 and t = 65, * P < 0.05 vs. t = 0 (paired 1-test),
P < 0.05 vs. nondiabetics (independent 1-test).
CCr of the study population was 33 2 ml!min. There was a
strong correlation between the estimated and measured Ccr (r
= 0.84, P <0.0001). Cr was similar in all drug groups.
Seventy percent of all the patients (diabetics, 75%; nondia-
betics, 65%) were taking calcium channel blockers on a long-
term basis at the time of the cardiac catheterization. The mean
dose of contrast medium injected during the protocol was 124
6 ml and was similar in all groups, with the exception of Group
3 (ANP), in which the mean dose was lower compared with that
in Group 1 (saline) (99 9 ml vs. 140 10 ml, P < 0.05). There
were no significant differences in the dose of contrast medium
between the diabetic and nondiabetic patients in any group or in
the total population.
Renal hemodynamics
Mean baseline RBF was consistently lower in patients with
diabetes mellitus than in nondiabetics in every group, and this
difference achieved statistical significance in Group 2, in all
experimental drug groups combined (Groups 2 to 4), and in all
groups combined (Groups 1 to 4) (Table 1). Likewise, baseline
renovascular resistance was higher in diabetics than nondiabet-
ics in each drug group, and this difference was statistically
significant for the population as a whole (91,039 17,258 vs.
40,774 5181, diabetics vs. nondiabetics, P < 0.01). Filtration
fraction was higher in patients with diabetes mellitus than in
nondiabetics (36 5% vs. 24 3%, P <0.05).
RBF rose, and renovascular resistance fell, in the population
as a whole over the course of the cardiac catheterization (P <
0.01). These renal hemodynamic changes were accounted for
largely by the behavior of the diabetic subpopulation, in which
there was a significant increase in RBF, and decline in renovas-
cular resistance, over time (P < 0.01), and at every time point
(P < 0.05 vs. t = 0). Among the nondiabetic patients, there was
a significant increase in RBF at t = 15 and t = 65 (129 13%,
132 10%, respectively, P < 0.05 vs. t = 0), but these
increases were significantly smaller than those of the diabetic
subpopulation at each time point (P < 0.05; Fig. 1).
Time, minutes
Fig. 2. Mean percent change in RBF during cardiac catheterization for
patients receiving all experimental drugs (Groups 2 to 4) combined
(solid line), or saline (dashed line). Symbols are (0) patients with
diabetes mellitus; (0) patients without diabetes mellitus. Timing of
ventriculogram and coronary angiogram as in Figure 1 legend. *
0.05 vs. t = 0 (paired t-test), P < 0.05 vs. nondiabetics (independent
f-test).
In Group I (saline control) as a whole, RBF rose significantly
over time (P < 0.01) and again, the increase among the patients
with diabetes mellitus was explanatory: RBF rose over time
only among the diabetics (P < 0.05); in the nondiabetic sub-
group, there was a significant increase in RBF at t 65 only
(Fig. 2).
RBF rose significantly over time only among the diabetic
patients in Group 2 (dopamine), Group 3 (ANP) and Group 4
(mannitol) (all P < 0.05). In Group 2, the increase in RBF in the
diabetic subgroup was greater than that of the nondiabetic
subgroup at each time point (P < 0.05).
When results from all the experimental drug groups (Groups
2 to 4) were combined, RBF rose significantly over time (P <
0.01). This rise, however, was due almost entirely to the change
in RBF in the diabetic subgroup (P < 0.01); there was no change
in RBF over time in the nondiabetic subgroup. At each time
point, the diabetic subgroup showed a significant increase in
RBF, compared to baseline (P < 0.05), which was greater than
that of the nondiabetic subgroup (P < 0.05; Fig. 2).
After five minutes of drug infusion and immediately before
the first injection of contrast medium (t = 5), RBF had risen
significantly among only the diabetic patients in Groups 2 to 4
combined (210 37% and 112 13% baseline RBF, for
diabetics and nondiabetics, respectively; P < 0.05 vs. baseline
RBF for diabetics only). In the saline control group at t = 5,
however, RBF had not changed significantly in either diabetics
or nondiabetics (110 14% and 110 23%, respectively).
There were no differences in baseline RBF or the change in
RBF at t = 5, t = 15 or t = 65 between patients taking or not
taking calcium channel blockers on a long-term basis.
The increase in RBF at t = 65 correlated inversely with the
baseline RBF (r =
—0.39, P < 0.01). This relationship was
explained completely by the behavior of the diabetic subpopu-
lation (r =
—0.54, P < 0.01). There was no relationship between
baseline RBF and a change in RBF at t 65 among nondiabet-
ics.
a)
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SAL DOP ANP MAN
Drug group
Fig. 3. Mean percent change in P 48 hours after cardiac catheter-
ization, by drug group: (SAL) saline; (EJOP) dopamine; (ANF) atrial
natriuretic peptide; (MAN) mannitol. Solid bars, patients without
diabetes mellitus; hatched bars, patients with diabetes mellitus. * JJ
0.05 vs. t = 0 (paired t-test), P < 0.05 vs. nondiabetics (independent
i-test).
Drug group
Incide
RC
ace of
N %
1. SAL (+)DM(—)DM 40
2. DOP (+)DM(-)DM
gb
3. ANP (+)DM(—)DM 50
83b
0
4. MAN (+)DM(—)DM 30
75b
0
a p < 0.05 vs. (—)DM in Groups 2 to 4 combined, Fisher exact test
b P < 0.05 vs. (—)DM within drug group, Fisher exact test
Plasma creatinine concentration
The P 48 hours after the catheterization, expressed as a
percentage of the baseline PCr, rose in the population as a whole
(118 5% baseline PCr' P < 0.05 vs. baseline), and that rise was
inversely proportional to the baseline RBF (r =
—0.33, P <
0.05). The increase in PCr in the population as a whole,
however, was due entirely to the rise in PCr among patients with
diabetes mellitus (diabetics 138 7% vs. nondiabetics 99 3%;
P < 0.05). When analyzed by individual drug group, the change
in Cr was significantly greater in diabetics than nondiabetics
for each group except the saline control (Fig. 3).
Table 2 shows the incidence of RCN by group, and according
to the presence or absence of diabetes mellitus. Overall, 19 of
50 patients (38%) developed RCN. The overall incidence of
RCN was similar in Groups 1 to 4.
When patients with and without diabetes mellitus were ana-
lyzed separately, however, striking differences were seen in the
incidence of RCN with the various drug protocols. Patients with
diabetes mellitus accounted for 16 of the 19 cases (84%) of
RCN. RCN developed in 16of 24 patients with diabetes mellitus
(67%), and among nondiabetics, in three of 26 (12%), a signifi-
cant difference (P < 0.0001, Chi-squared). The relative risk for
Drug group Intake
1927 257
Output Balance
1. SAL 1304 279 623 282
(+)DM 1550 587 940 365 610 613
(—)DM 2179 169 1547 388 632 297
2. DOP 2453 230 1778 224 676 235
(+)DM 2727 389 1811 327 915 182
(—)DM 2180 231 1744 333 436 432
3. ANP 1915 309 2028 461 —113 383
(+)DM 1753 428 1628 507 125 693
(—)DM 2078 495 2429 793 —351 408
4. MAN 3173 485 2416 406 757 321
(+)DM 3470 696 2043 172 1427 570
(—)DM 2936 725 2715 725 221 114
Groups 2—4 2523 204 2028 194 496 179
(+)DM 2665 311 1824 198 841 263
(—)DM 2391 273 2218 327 172 221
Groups 1—4 2378 170 1851 168 527 150
(+)DM 2430 288 1638 190 792 237
(—)DM 2333 203 2035 264 298 182
RCN conferred by diabetes mellitus was 5.78 (95% CI, 1.92 to
17.38). Comparable disparitieswere seen between diabetics and
nondiabetics in each of the groups receiving the experimental
drugs—dopamine, ANP or mannitol. None of the nondiabetic
patients in these groups developed RCN. In contrast, 83%, 83%
and 75% of the diabetics in these groups, respectively, devel-
oped RCN. Within each of these groups, the difference in the
incidence of RCN between diabetics and nondiabetics was
significant (P < 0.05, Fisher exact test). In the saline control
group, however, there was no difference between diabetics and
nondiabetics with respect to the incidence of RCN.
Among nondiabetics, the incidence of RCN was significantly
lower in Groups 2 to 4 combined, than in Group 1 (0% vs. 38%,
P <0.05, Fisher exact test). Among diabetics who received one
of the experimental drugs, however, the incidence of RCN
tended to be higher than among those who received saline (81%
vs. 43%), although the difference was not statistically signifi-
cant.
The incidence of RCN was not significantly different in the
presence or absence of long-term calcium channel blocker
therapy (41% and 27%, respectively; P 0.52, Chi-squared).
Fluid balance
Forty-one of the 50 patients had complete records made of
fluid intake and output during the 24 hours following cardiac
catheterization. Of the nine patients without data collected, five
were diabetic, five received saline, two ANP, one mannitol and
one dopamine. Two developed RCN, both of whom were
diabetics who had received ANP.
Table 3 shows the mean fluid balance during the first 24 hours
after cardiac catheterization for patients by drug group and
according to the presence and absence of diabetes mellitus. Net
fluid balance was positive for all groups except the nondiabetics
who received ANP, and was the same in diabetics and nondi-
abetics (732 312 ml vs. 961 249 ml, respectively; NS). For
the population as a whole, the greater the increase in PCr at 48
hours, the more positive the net fluid balance (r = 0.37, P <
0.05). That same relationship held for nondiabetics (r 0.51, P
<0.05), but not for diabetics, in whom there was no significant
relationship between fluid balance and change in Cr Among
80
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Table 3. Fluid balance (ml) at 24 hours
Table 2. Incidence of RCN by drug group, diabetics and
nondiabetics
Weisberg et a!: Radiocontrast nephropathy and diabetes 263
patients with positive net fluid balance, the risk of RCN was
higher in diabetics than nondiabetics in the population as a
whole (P < 0.05), and in patients receiving dopamine, ANP and
mannitol (P < 0.01).
Four patients had a net fluid loss of more than 500 ml in the
24 hours after cardiac catheterization. Two of those patients,
both diabetic, developed acute renal failure, one of whom had
received saline and the other ANP.
Discussion
Previous studies have shown that diabetes mellitus increases
the risk of RCN [1—4]. The results of the present study corrob-
orate those observations. The incidence of RCN was signifi-
cantly higher in the patients with diabetes mellitus than in those
without, and patients with diabetes mellitus had approximately
six times the risk of RCN as nondiabetics.
Paradoxically, the incidence of RCN was highest among the
diabetic patients who received the vasodilator/diuretic drugs
postulated to prevent RCN: dopamine, ANP and mannitol.
Among the diabetic patients, the incidence of RCN was higher
in all the experimental drug groups than in the saline control
group, although that difference did not achieve statistical sig-
nificance. In each of the vasodilator/diuretic drug groups, the
incidence of RCN was significantly higher in patients with
diabetes mellitus than in those without. In the saline control
group, however, there was no difference between diabetic and
nondiabetic patients with respect to the incidence of RCN.
These findings strongly implicate the experimental drugs used
in the present study in the increased risk of diabetic patients for
RCN. Prerenal azotemia cannot explain the rise in Cr' since
the mean net fluid balance was positive for all groups in which
acute renal failure developed, and since only two of the
nineteen patients who developed acute renal failure were doc-
umented to have had a significant net fluid loss during the
post-catheterization period.
Because of those observations, and because of the prominent
role given to immediate renal hemodynamic changes in the
proposed pathogenesis of RCN [8, 9], we sought to explain the
different risks of diabetic and nondiabetic patients by examining
the change in RBF during exposure to contrast medium. We
found that the rise in RBF throughout the cardiac catheteriza-
tion in the population as a whole was mainly due to the change
in RBF in the diabetic subpopulation (Fig. 1). This disparity in
the renal hemodynamic responses of the diabetics and nondia-
betics in the population as a whole was explained, in turn, by
the behavior of the patients receiving the experimental drugs
(Groups 2 to 4). Only the diabetic patients showed a significant
increase in RBF over time. In the saline control group, how-
ever, the responses of the diabetics and nondiabetics were not
nearly as disparate as they were in the experimental groups
(Fig. 2).
The patients with diabetes mellitus in our study had signifi-
cantly lower RBF at baseline than the nondiabetic patients,
despite comparable Car. This renal hemodynamic profile, and
the resulting elevation in filtration fraction, have been described
previously in type I diabetes, both early [16] and advanced [21,
23, 24], and in early type II diabetes [21, 25, 26]. The present
study suggests that these renal hemodynamic characteristics
may also be implicated in the predisposition of diabetic patients
to RCN. The baseline RBF was inversely proportional to both
the increase in RBF at the end of the cardiac catheterization and
to the rise in PCr after exposure to contrast medium in the
patients with diabetes mellitus only. Thus, the baseline renal
vasoconstriction and/or the renal vasodilation during the pro-
cedure appears to have predisposed the diabetic patients to
RCN.
The results of the present study do not explain why the
unique renal hemodynamic characteristics of the patients with
diabetes mellitus should have predisposed them to RCN. It is
interesting to speculate about the role of medullary oxygen
economy in this regard. While contrast medium administration
does not appear to be associated with a reduction in global RBF
in humans [20], there is evidence from studies of rats that it may
cause a redistribution of blood flow from the medulla to the
cortex [27]. Such a reduction in medullary blood flow would
result in a decrease in oxygen delivery to a region of the kidney
with very low oxygen tension under even basal conditions.
Indeed, RCN in the rat is manifested by ischemic damage of the
medullary thick ascending limb of Henle's loop [28].
How might the marked increase in global RBF experienced
by the diabetic patients in the present study be associated with
an exacerbation of medullary ischemia? Some light is shed on
this question by a recent study in rats [29] showing an associ-
ation between renal vasodilation induced by glycine infusion
during contrast medium exposure and an increase in outer
medullary damage. In that study, the increase in RBF was
accompanied by a sharp decrease in medullary oxygen tension,
perhaps partly due to shunting of blood away from that region.
Similarly, medullary hypoxia may have developed with the
experimental drugs used in our study for at least two reasons.
First, it is possible that the increase in global renal blood flow
seen in the present study was accompanied by an intrarenal
redistribution of blood flow, reducing medullary oxygen deliv-
ery and enhancing susceptibility to ischemic injury with con-
trast medium exposure [27—30]. Diabetic animals [31—33] and
humans [34] appear to have deficient endothelium-dependent
vasodilation, that is, a lack of, or insensitivity to, endothelium-
derived relaxing factor (EDRF). That would explain the basal
renal vasoconstriction seen in our diabetic patients and their
exaggerated renal vasodilation with dopamine, ANP and man-
nitol, all of which have endothelium-independent vasodilatory
action. (Such effects were seen with ANP administration to rats
made EDRF-deficient [35]). If such exaggerated renal vasodi-
lation were predominantly cortical (as appears to be the case
with dopamine administration [36]), a medullary "steal" might
ensue with subsequent contrast medium infusion. Supporting a
critical role for medullary oxygen delivery in the pathogenesis
of RCN is the observation that inhibiting EDRF synthesis
reduces renal medullary oxygen tension and exacerbates con-
trast medium-associated damage in rats [37].
Second, oxygen demand may have risen due to increased
distal solute delivery accompanying the use of the experimental
drugs, all of which would increase solute delivery to the
medulla by blocking proximal sodium reabsorption and/or in-
creasing glomerular filtration rate.
The combination of these two factors would clearly work
together to reduce the oxygen supply:demand ratio, predispos-
ing to ischemic injury. In addition, the kidneys of diabetic
patients may be more susceptible to ischemia at a given level of
solute delivery than those of nondiabetics [19].
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In contrast to the diabetic patients, the nondiabetic subpop-
ulation was significantly protected from RCN by the experimen-
tal drugs used in the present study. Indeed, the incidence of
RCN among nondiabetics in all the experimental drug groups
was zero. Commonly accepted formulations of the pathogenesis
of RCN [8, 9] would lead to the conclusion that the protective
effect was due to preservation of global renal blood flow during
contrast medium exposure. Figure 2, however, shows that RBF
of nondiabetic patients who received the experimental drugs
was no different from that of nondiabetic patients in the saline
control group, while the incidence of RCN was significantly
higher in the latter group. The protection may be due to the
increased tubular flow rate and, thus, a reduction in the
concentration of contrast medium to which the kidney is
exposed. Such an explanation is purely speculative, however.
The mechanism whereby these drugs protect nondiabetic pa-
tients with chronic renal insufficiency from RCN is not evident
based on the results of the present study.
In summary, the higher risk of diabetic patients for RCN was
related to their exaggerated renovascular reactivity, expressed
both as renal vasoconstriction at baseline, and as renal vasodi-
lation during contrast medium exposure in the presence of renal
vasodilator/diuretic drugs. In contrast, the nondiabetic patients
in our study were significantly protected from RCN by the
experimental drugs, without any attributable increase in global
renal blood flow. Thus, the experimental drugs used in the
present study (dopamine, ANP and mannitol) reduced the
incidence of RCN in nondiabetics and tended to increase the
incidence in diabetics, probably through different mechanisms.
Our study supports the use of ANP, mannitol or dopamine to
prevent RCN only in patients without diabetes mellitus. The
data further suggest that those same drugs, two of which are
commonly used during contrast medium infusion, may be
harmful in diabetic patients.
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